Condition

Erosive Gastroesophageal Reflux Disease (3)

Non-Erosive Reflux Disease (1)

Overall Status

Completed (3)

Sign in for free

Phase

phase 2 (1)

phase 3 (1)

Sponsor

Daewoong Pharmaceutical Co. LTD. (1)

Hanmi Pharmaceutical Company Limited (1)

Nycomed (1)

Collaborator

Intervention

dwp14012 (1)

dwp14012 placebo (1)

esomeprazole (1)

esomeprazole placebo (1)

hgp1705 (1)

hgp1705 placebo (1)

hip1601 (1)

hip1601 placebo (1)

pantoprazole (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Industry (3)

Study Type

Interventional (2)

Observational (1)

erosive gastroesophageal reflux disease

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Erosive Gastroesophageal Reflux Disease Trial in Seoul (HIP1601, HGP1705, HIP1601 Placebo)

Completed

Erosive Gastroesophageal Reflux Disease

HIP1601
+3 more

Seoul, Korea, Republic of

Asan Medical Center

Nov 26, 2020

Erosive Gastroesophageal Reflux Disease Trial in Sungdong-gu (DWP14012, Esomeprazole, DWP14012 )

Completed

Erosive Gastroesophageal Reflux Disease

DWP14012
+3 more

Sungdong-gu, Seoul, Korea, Republic of

Hanyang University Medical Center

Sep 1, 2020

Pantoprazole in Patients Older Than 12 Years With Reflux

Completed

Has Results

Erosive Gastroesophageal Reflux Disease
Non-Erosive Reflux Disease

Pantoprazole

Aachen, Germany
+1152 more

May 4, 2012